Industry news, page-428

thanks for the detailed response @comincon

when I said long term profitability with psychedelics I probably should have said creating a 'recurring revenue' stream. The benefits are there as you have highlighted however we know big Pharma want drugs with recurring revenue into the foreseeable future and not a solution that will heal a patient completely (as sad as that is).

Hence the question around whether drugs formulated in Psychedelics space can command multiples on their future earnings like our CBD drug program. Will big Pharma pay up for a drug that they can only sell to a patient once or twice? Or is the value recurring in the sense that there is always expected to be a huge market for mental health and new patients will be captured all the time.

Just trying to think through how one values the Psychedelics business if we don't re-sell our drug to the same person each month or each cycle because they then no longer suffer mental health problems